SCHEMBL24944969

SCHEMBL24944969

CNc1nc(Nc2ccc(N3CCOCC3)cc2OC)c(C(N)=O)nc1-c1cncc2c1ncn2C

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LRRK2 Q5S007 3/20 0.51
▸ MAPK10 P53779 3/20 0.51
▸ MAPK8 P45983 2/20 0.51
▸ MAPK9 P45984 2/20 0.51
▸ ALK Q9UM73 5/20 0.48
▸ INSR P06213 3/20 0.48
▸ PTK2 Q05397 4/20 0.47
▸ IGF1R P08069 2/20 0.47
▸ DCLK1 O15075 2/20 0.47
▸ CDK2 P24941 2/20 0.47
▸ PLK1 P53350 2/20 0.47
▸ PLK3 Q9H4B4 2/20 0.47
▸ TNK2 Q07912 2/20 0.47
▸ CDC7 O00311 1/20 0.47
▸ PLK4 O00444 1/20 0.47
▸ CHEK1 O14757 1/20 0.47
▸ AURKA O14965 1/20 0.47
▸ PDPK1 O15530 1/20 0.47
▸ DAPK3 O43293 1/20 0.47
▸ DYRK3 O43781 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30206251 0.94 LRRK2 (0.51) LRRK2MAPK10MAPK8MAPK9ALK
SCHEMBL29173409 0.94 LRRK2 (0.51) LRRK2MAPK10MAPK8MAPK9ALK
SCHEMBL24944156 0.91 MAPK9 (0.40) LRRK2MAPK10MAPK8MAPK9ALK
SCHEMBL30205517 0.91 MAPK9 (0.48) LRRK2MAPK10MAPK8MAPK9ALK
SCHEMBL24943795 0.91 MAPK9 (0.44) LRRK2MAPK10MAPK8MAPK9ALK
SCHEMBL24944367 0.91 MAPK9 (0.48) LRRK2MAPK10MAPK8MAPK9ALK
SCHEMBL24943791 0.88 EML4 (0.48) ALKCDK2AURKALCKRET
SCHEMBL30206122 0.86 LRRK2 (0.42) LRRK2MAPK10MAPK8MAPK9ALK
SCHEMBL29173575 0.86 LRRK2 (0.42) LRRK2MAPK10MAPK8MAPK9ALK
SCHEMBL24944174 0.86 ALK (0.52) MAPK10MAPK8MAPK9ALKCDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4373817-B1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER ASTRAZENECA AB (SE) 2025-05-21 — — EP claimed
EP-4373817-A1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER Astrazeneca AB (SE) 2024-05-29 — — EP claimed
CN-117693503-A Substituted pyrazine-2-carboxamides as HPK1 inhibitors for the treatment of cancer 阿斯利康(瑞典)有限公司 2024-03-12 — — CN claimed
WO-2023001794-A1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER ASTRAZENECA AB (SE) 2023-01-26 — — WO claimed
EP-4373817-A1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER Astrazeneca AB (SE) 2024-05-29 — — EP disclosed
CN-117693503-A Substituted pyrazine-2-carboxamides as HPK1 inhibitors for the treatment of cancer 阿斯利康(瑞典)有限公司 2024-03-12 — — CN disclosed
WO-2023001794-A1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER ASTRAZENECA AB (SE) 2023-01-26 — — WO disclosed
WO-2023001794-A1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER ASTRAZENECA AB (SE) 2023-01-26 — — WO disclosed
Send feedback